RNAC

Cartesian Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 7/10
  • Value↓ 0/10
Cartesian Therapeutics sales and earnings growth
RNAC Growth
Good
  • Revenue Y/Y↓ -92.81%
  • EPS Y/Y↓ -12.05%
  • FCF Y/Y↓ -144.93%
Cartesian Therapeutics gross and profit margin trends
RNAC Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -4658.60%
  • ROIC 5Y↓ -125.07%
Cartesian Therapeutics net debt vs free cash flow
RNAC Risk
Great
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Cartesian Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗